Applied Clinical Trials October Recap
Our October issue focused on the current state of outsourcing with additional coverage around site networks and risk-based quality management.
This October, Applied Clinical Trials focused on the topic of new-age outsourcing. Led by the rise of integrated research organizations (IROs), providers are finding new and innovative ways to design their trials. In the case of IROs, this new approach enhances diversity and access by bringing clinical trials directly to patient communities, as opposed to more traditional research sites.
On the business side of outsourcing, partnering with a functional service provider (FSP) is becoming critical. These providers are now supporting sponsors through oversight and leveraging business operations data, giving those who partner with them a clear edge in trial execution.
In addition to the current outsourcing landscape, ACT’s October issue also provided key insights on site networks and risk-based quality management (RBQM).
With November on the horizon, the following slideshow provides a look back at the previously mentioned topics we covered in October.
Image Credit: © Lucas - stock.adobe.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
